

1fw

PATENT
ATTORNEY DOCKET NUMBER: 50073/010003

Certificate of Mailing: Date of Deposit: July 20, 2004

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Colleen Coyne

Printed name of person mailing correspondence

Colleen Coyne

Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Gudarz Davar et al.	Art Unit:	1614
Serial No.:	10/796,825	Examiner:	
Filed:	March 9, 2004	Customer No.:	21559
Title:	ANALGESIC METHODS USING ENDOTHELIN RECEPTOR LIGANDS		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449.


Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

Under 35 U.S.C. § 120, this application relies on the earlier filing date of application serial number 10/200,923, which was filed on July 23, 2002. The following references on the PTO 1449 forms were submitted to and/or cited by the Office in the prior application and, therefore, copies of these references are not provided for this application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 20 July 2004



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Sheet 1 of 3

SUBSTITUTE FORM PTO-1449 (MODIFIED) INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No. 50073/010003
		Serial No. 10/796,825
		Applicant Gudarz Davar et al.
		Filing Date March 9, 2004
		Group 1614
		IDS Filed July 20, 2004

U.S. PATENTS

Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	5,658,943	08/19/97	Berryman et al.			
	4,984,570	01/1991	Langen et al.			
	6,436,438 B1	08/2002	Momberger et al.			
	6,019,988	2/2000	Parab et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION


Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 99/56761	11 Nov 99	PCT			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)


	Kitazono et al., "Dilatation of the Basilar Artery in Response to Selective Activation of Endothelin B Receptor in Vivo," <i>The Journal of Pharmacology and Experimental Therapeutics</i> 273:1-6 (1995).
	Ikeda et al., "Involvement of G-Protein-Activated Inwardly Rectifying K ⁺ (GIRK) Channels in Opioid-Induced Analgesia," <i>Neuroscience Research</i> 38 pages 113-116, 2000.
	Kamei et al., "Effect of Diabetes on Bradykinin-Induced Thermal Hyperalgesia in Mice," <i>European Journal of pharmacology</i> 390:113-118 (2000).
	Carducci et al., "Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics," <i>J. Clin. Oncol.</i> 20(8):2171-80 (2002).
	Chen et al., "Endothelin-1-mediated inhibition of inward barium current in sensory neuronal hybrid (F-11) cells," Abstract No. 634.5, <i>Society for Neuroscience, 30th Annual Meeting, New Orleans, LA, November 4-9 (2000).</i>
	Cheng et al., "Endothelin inhibitors," <i>Ann. Reports in Medicinal Chem., Ed. by A.M. Doherty, Academic Press, Sect. II, Chap. 7: 61-70 (1997).</i>
	Dahlof et al., "Regional haemodynamic effects of endothelin-1 in rat and man: unexpected adverse reaction," <i>J. Hypertens.</i> 8(9):811-7 (1990).
	D'Amico et al., "Selective and non-selective ET antagonists reveal an ET(A)/ET(B) receptor mediated ET-1-induced antinociceptive effect in PAG area of mice," <i>Life Sci.</i> 61(25):PL 397-401 (1997).
	Davar, "Endothelin-1 and metastatic cancer pain," <i>Pain Medicine</i> 2(1):24-27(2000).
	Davar et al., "Behavioral signs of acute pain produced by application of endothelin-1 to rat sciatic nerve," <i>Pain</i> 9:2279-2283 (1998).
	De-Melo, et al., "Articular nociception induced by endothelin-1, carrageenan and LPS in naive and previously inflamed knee-joints in the rat: inhibition by endothelin receptor antagonists," <i>Pain</i> 77(3):261-9 (1998).

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.



SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50073/010003 Serial No. 10/796,825 Applicant Gudarz Davar et al. Filing Date March 9, 2004 Group 1614 IDS Filed July 20, 2004
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
	Fareed, et al., "Pharmacological characterization of acute pain behavior produced by application of endothelin-1 to rat sciatic nerve," <i>J. Pain</i> 1:46-53 (2000).	
	Ferreira, et al., "Endothelin-1 participation in overt and inflammatory pain," <i>J. Cardiovasc. Pharmacol.</i> 13 Suppl 5:S220-2 (1989).	
	Gokin et al., "Selective Excitation of nociceptive sensory fibers by endothelin-1 applied to the rat plantar hindpaw," Abstract No. 634.4, <i>Society for Neuroscience, 30th Annual Meeting, New Orleans, LA, November 4-9</i> (2000).	
	Gokin et al., "Local injection of endothelin-1 produces pain-like behavior and excitation of nociceptors in rats," <i>J. Neurosci.</i> 21(14):5358-66 (2001).	
	Graido-Gonzalez et al., "Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis," <i>Blood</i> 92(7):2551-5 (1998).	
	Griswold, et al., "Endothelin B receptor modulates inflammatory pain and cutaneous inflammation," <i>Mol. Pharmacol.</i> 56(4):807-12 (1999).	
	Jarvis, et al., "ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain," <i>Eur. J. Pharmacol.</i> 388(1):29-35 (2000).	
	Khodorova et al., "Endothelin-B receptor mediated modulation of pain-like behavior induced by the subcutaneous injection of Endothelin-1 into the rat plantar hindpaw," Abstract No. 672, <i>American Pain Society, 20th Annual Meeting, Phoenix, AZ, April 19-22</i> (2001).	
	Kopetz, et al., "Endothelin-1 as a target for therapeutic intervention in prostate cancer," <i>Invest. New Drugs</i> 20(2):173-82 (2002).	
	Lawrence, et al., "Evidence for ETA and ETB receptors in rat skin and an investigation of their function in the cutaneous microvasculature," <i>Br. J. Pharmacol.</i> 115(5):840-4 (1995).	
	Nelson et al., "Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate," <i>Nat. Med.</i> 1(9):944-9 (1995).	
	Palacios et al., "Endothelin Etb Receptors Counteract Venokonstrictor Effects of Endothelin-1 in Anesthetized Rats," <i>Life Sciences</i> 63:1239-1249 (1998).	
	Piovezan et al., "Endothelins potentiate formalin-induced nociception and paw edema in mice," <i>Can. J. Physiol. Pharmacol.</i> 75(6):596-600 (1997).	
	Piovezan et al., "Effects of endothelin-1 on capsaicin-induced nociception in mice," <i>Eur. J. Pharmacol.</i> 351(1):15-22 (1998).	
	Piovezan et al., "Endothelin-1-induced ET(A) receptor-mediated nociception, hyperalgesia and oedema in the mouse hind-paw: modulation by simultaneous ET(B) receptor activation," <i>Br. J. Pharmacol.</i> 129(5):961-8 (2000).	
	Pomonis et al., "Expression and localization of endothelin receptors: implications for the involvement of peripheral glia in nociception," <i>J. Neurosci.</i> 21(3):999-1006 (2001).	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		



SUBSTITUTE FORM PTO-1449, U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Attorney Docket No. 50073/010003 Serial No. 10/796,825 Applicant Gudarz Davar et al. Filing Date March 9, 2004 Group 1614 IDS Filed July 20, 2004
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)		
	Raffa et al., "Characterization of endothelin-induced nociception in mice: evidence for a mechanistically distinct analgesic model," <i>J. Pharmacol. Exp. Ther.</i> 278(1):1-7 (1996).	
	Raffa et al., "Endothelin-induced nociception in mice: mediation by ETA and ETB receptors," <i>J. Pharmacol. Exp. Ther.</i> 276(2):647-51 (1996).	
	Rogalski, et al., "Activation of the endothelin receptor inhibits the G protein-coupled inwardly rectifying potassium channel by a phospholipase A2-mediated mechanism," <i>J. Neurochem.</i> 72(4):1409-16 (1999).	
	Takai, et al., "A potent and specific agonist, Suc-[Glu9,Ala11,15]-endothelin-1(8-21), IRL 1620, for the ETB receptor," <i>Biochem. Biophys. Res. Commun.</i> 184(2):953-9 (1992).	
	Wu et al., "Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist," <i>J. Med. Chem.</i> 40(11):1690-7 (1997).	
	Yamamoto et al., "Analysis of the role of endothelin-A and endothelin-B receptors on nociceptive information transmission in the spinal cord with FR139317, an endothelin-A receptor antagonist, and sarafotoxin S6c, an endothelin-B receptor agonist," <i>J. Pharmacol. Exp. Ther.</i> 271(1):156-63 (1994)	
	Yohn, et al., "Autoregulation of endothelin-1 secretion by cultured human keratinocytes via the endothelin B receptor," <i>Biochim. Biophys. Acta</i> 1224(3):454-8 (1994).	
	Zhou, et al., "Endothelin-1 activates ET(A) receptors to increase intracellular calcium in model sensory neurons," <i>NeuroReport</i> 12(17):3853-7 (2001).	
EXAMINER		DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.		